MedPath
Found 2 clinical trials|View Analysis
Sort by:

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: SH-1028 tablets
Drug: Placebo SH-1028 tablets
First Posted Date
2023-10-12
Last Posted Date
2023-10-12
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Target Recruit Count
242
Registration Number
NCT06080776
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: SH-1028 tablets
Drug: Placebo SH-1028 tablets
Drug: Placebo Gefitinib
Drug: Gefitinib
First Posted Date
2020-01-27
Last Posted Date
2020-01-27
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Target Recruit Count
240
Registration Number
NCT04239833
© Copyright 2025. All Rights Reserved by MedPath